Skip to main content

Table 2 Selected studies of neoadjuvant chemoradiotherapy

From: The role of radiotherapy in multimodal treatment of pancreatic carcinoma

Study Institution Number of patients Total dose of RT (Gy) Chemo-therapy Median OS (months) 1(2,4,5)-year-OS-rate (%) Rate of local recurrence (%) Rate of resectability (%) Rate of clear resections
Hoffman et al. 1998[36, 74]
multi-centric* 		53 50.4 5-FU/MMC 9.7 all pts 15.7 res 2y: 27 res 24/53 (26%) 3/24 (13%) res 24/53 (45%) n.a.
Snady et al. 2000[39]
Mount Sinai* 		159
68* (20 res*)
vs 91 adj 		54 +14 Gy 5-FU/Cis/
Streptozotocin 		23.6* (32 res)
vs 14.0 		1 y:
86*(89)vs 64
2y:
58*(60) vs 32
3y:
27*(40)vs 17 		n.a. 20/68 (29%) - 95% neo 84% adj
Breslin et al. 2001[75]
MDACC# 		132 45 or 50.4 Gy
or 10 × 3 Gy
± IORT 		5-FU, or Tax or Gem 21 1y: 75
2y: 40
5y: 23 		8/132 (6%) - 88%
Sasson AR et al.2003[76]
FCCC* 		116
61 neo
55 adj 		50.4 5-FU/MMC or Gem All 18 neo 23 adj 16 n.a. n.a. - 39%
n.a.
n.a.
White et al. 2005[68]
Duke# 		193
i.p.r.:102
i.l.a.: 91 		45 +5.4 Gy 5-FU
or Gem 		23
39 i.p.r.
20 i.l.f. 		3y: 37 res
5y: 27 res 		n.a. 70/193 (36%)
54/102 (53%)
16/91 (18%) 		73%
n.a.
n.a.
Evans et al. pII 2008[11] * MDACC i.p.r.: 86
(64 res) 		30 Gy
(in 10 fractions) 		Gem
(7 × 400 mg) 		23
34 		1y: 92 res
2y: 62 res
5y: 36 res 		7/64 (11%) 64/86 (74%) 11%
Golcher et al. 2008[43]# Erlangen 79
21 neo*
58 res^ 		50.4 Gy
+5.4 Gy 		5-FU
or Gem 		54 neo-res
21 no CRT res 		2y: 56 neo-res
43 no CRT res 		n.a. 21/103(20%) 90% neo
78% res
Gillen et al. meta-analysis 2010[44] All: 4,394
i.p.r.: 32%
i.l.a.: 51%
both: 17% 		>60%: 40-60 Gy 50% 5-FU(+)
40% Gem(+) 		i.p.r.: 23
i.l.a.: 21 		i.p.r/i.l.a.
1y 78/78
2y 47/50 		n.a. i.p.r.: 74%
I.l.a.: 33% 		i.p.r.: 82%
I.l.a.: 79%
Stessin et al. SEER 2008[35] i.p.r.: 3,885
70 neo
1,478 adj RT
2,337 obs 		n.a. n.a. 23 neo
17 adj
12 obs 		Neo/adj/obs
1y 79/68/50
2y 49/34/28 		n.a. n.a. n.a.
  1. Abbreviations: (+) = or additional agent, 5-FU = 5-fluorouracil; adj = adjuvant therapy; Cis = cisplatin; FCCC = Fox Chase Cancer Center, Philadelphia, PA; Gem = gemcitabine; Gy = Dose in Gray; i.p.r = initially potentially resectable; i.l.a. = initially locally advanced, MDACC = M.D. Anderson Cancer Center Houston, TX; MMC = mitomycin C; n.a. = not available; neo = neoadjuvant; obs. = observation, no adjuvant therapy, OS = overall survival; res = resected patients, RT = radiotherapy; Tax = paclitaxel; vs. = versus.
  2. *initially unresectable patients ± resection after chemoradiotherapy;
  3. §this study indicates overall survival as explained: (1) patients with chemoradiotherapy (2) numbers in brackets: patients with chemoradiotherapy and resection (3) numbers to the right of 'vs.': patients after primary resection.
  4. ^This study compared patients with immediate tumour resection (n = 58) with non-resectable patients who subsequently underwent neoadjuvant chemoradiotherapy
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us